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Objectives: the objective was to explore the consistency of DNA methylation pattern between 
peripheral blood and breast tumor tissue, and discussed the potential of using blood as a surrogate 
epigenetic biomarker to study the relationship between breast cancer and shiftwork. 
Methods: systematic review on studies analyzing the concordance or correlation of DNA methylation 
level between breast tumor tissue and peripheral blood was conducted. The results of eligible studies 
were summarized to find the specific genes that had consistent methylation pattern in both tumor 
tissues and blood. Then the blood samples from the well-established Danish cohort were used to 
perform epigenome-wide association analysis to show the genome-wide methylation pattern in the 
blood. Cohort studies on each gene and its relationship between breast cancer were searched to discuss 
whether that gene might be a precursor for breast cancer. 
Results: the DNA methylation array of the Danish cohort in this study detected 5409 CpG sites that 
differentially methylated between day workers and night shift workers. Totally 4750 genes showed 
significantly differential methylation level between the two groups. Among 22 candidate genes and 3 
repetitive elements from the eligible studies and public datasets,  methylation patterns of the five 
genes, IGF2, BRCA1, GSTP1, P16 and MGMT were consistent between blood and breast tumor tissues 
among breast cancer patients and showed significant difference between day shift workers and night 
shift workers, which implicated that it could be potential biomarkers for the screening of breast cancer 
and as a surrogate to study the relationship between breast cancer and circadian disruption. 
Conclusion: aberrant methylation status of five genes, IGF2, BRCA1, GSTP1, P16 and MGMT, might be a 
promising epigenetic biomarker for early detection and diagnosis of breast cancer, and it can also be a 
surrogate biomarker to study the relationship between breast cancer and night shiftwork. 
Keywords: DNA methylation, breast cancer, night shiftwork, Chronic Disease Epidemiology 
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Breast cancer (BC) is the most common cancer in women around the world, and accounts for 15% of 
cancer deaths among women, which is the leading cause of cancer death in females worldwide. (1) Early 
detection and diagnosis of breast cancer has ignited broad discussion among scientists during the past 
several decades. Some studies showed that the epigenetic alterations, especially DNA methylation of 
repetitive elements or specific genes, might be potential biomarkers for breast cancer detection. Night 
shift work has long been assumed to be a risk factor for breast cancer. Some studies showed an elevated 
incidence of breast cancer among night shift workers. (2) How night shift work impacts the 
carcinogenesis of breast cancer remains unclear. Here we hypothesized that night shift work might be 
associated with DNA methylation of certain genes that are related to breast cancer. 
 
DNA methylation is an important epigenetic mechanism involving direct chemical modification to DNA 
that can affect genetic performance without changing DNA sequences. It refers to the process of a 
methyl group covalently bonded to the 5' carbon position of the cytosine under the action of DNA 
methyltransferases (DNMTs) to form 5-methylcytosine (5mC). DNA methylation typically occurs at CpG 
islands that possess functional importance. (3) Numerous studies have shown that DNA methylation can 
cause changes in chromatin structure, DNA conformation, stable gene silencing, and the way DNA 
interacting with proteins, thereby controlling gene expressions. Aberrant DNA methylations, including 
hypermethylation within promotor regions that followed by inactivation of tumor-suppressor genes and 
global hypomethylation inducing genomic instability or overexpression of oncogenes, are involved in 
carcinogenesis of different cancer types, including breast cancer. (4) DNA methylation also has high 
value in detecting and preventing breast cancer.  
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The development of adjuvant treatment combined with promotion of screening programs and advanced 
diagnostic techniques have improved the outcome of breast cancer and decreased the mortality rate of 
breast cancer during the past couple of decades. However, there are still around one third of breast 
cancer patients developing metastasis and eventually died from the disease. (5) Therefore, more 
effective methods to detect breast cancer at an early stage are needed.  
 
Most recently, there have been many studies on using blood as a surrogate epigenetic biomarker for the 
detection and diagnosis of breast cancer. Several studies showed correlation of methylation patterns 
between peripheral blood samples and breast tumor tissues. If further study can confirm the 
concordance between the two tissues, blood may be utilized as a promising biomarker for screening and 
diagnosis. It is obvious that blood as a surrogate biomarker has several distinct advantages. It is non-
invasive, and comparing to biopsy blood test is more convenient and accessible. Most existing studies 
tested the association between DNA methylation patterns in the blood and breast cancer risk, and did 
not focus on the consistency between blood and breast tissues. Therefore, the evidence that DNA 
methylation level in the blood was associated with breast cancer was not sufficient to make the 
inference that DNA methylation in the peripheral blood can represent DNA methylation pattern in the 
breast tumor tissues, thus can be used as a surrogate biomarker to detect breast cancer for individuals.  
 
Therefore, this study has two specific objectives. The first objective of this study is to explore the 
consistency of DNA methylation pattern between blood and breast tumor tissues, and detect the 
candidate genes of which the DNA methylation level could be used to predict breast cancer. The second 
objective is to observe whether night shift work is significantly associated with aberrant methylation of 
those candidate genes using genome-wide methylation analysis. 
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Materials and methods 
Study population 
Population in the selected studies  
In the systematic review, participants in the selected studies were female breast cancer patients and 
normal controls. Some of the studies were case-only, and no normal controls were included, of which 
the comparison of DNA methylation level was observed among breast tumor tissue, peripheral blood 
and normal breast tissue. The details of the studies were listed in Table 1.  
 
Population in the Danish cohort 
The blood samples for the DNA methylation assay in this study were collected from the participants of 
the Danish prospective cohort study “Diet, Cancer and Health”. In the Danish cohort study, all the 
female subjects were recruited between December 1993 and May 1997, and followed forward. The 
subjects recruited were aged 50 to 64 years old, with no diagnosis of any cancer registered in the Danish 
Cancer Registry, and born in Denmark. The information on lifestyles and other characteristics including 
shift work were gathered through questionnaire and interview. Participants provided their blood sample 
after the end of visit to the study center. Females participants that met the following criteria were 
selected: 1) had blood samples that were available for methylation analysis; 2) provided information on 
history of shift work. Shift work was defined as working starting from 19:00h or later and ending before 
09:00h. Totally 117 female participants were eligible for this study. Among the 117 eligible participants, 
19 of them are exposed to long-term (defined as ≥ 10 years of history) night shift work and the 
remaining 98 were day workers who had never been exposed to shift work. Age and total folate intake 
were not significantly differed between night shift workers and day workers. In our study, we randomly 
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selected 10 night shift workers from 19 long-term shift workers and 10 day workers were selected 
matching on age (± 2 yrs) and total folate intake (± 55 μg/day).  All the blood samples collected were 
frozen and stored at -150 Celsius. Details of the Danish cohort study and the procedures of collecting 
blood sample were described in the previous study. (6)  
 
Data collection 
Data from the systematic review on concordance between breast tissue and peripheral blood 
Papers were read through to decide if the study is eligible for further review. After being selected, the 
following information of the studies was listed: study, sample type, sample size, and candidate genes or 
array. Each gene that met the following criteria were analyzed in our Danish cohort: 1) showed 
significant different DNA methylation level between breast tumor tissue and normal breast tissue if 
comparison with normal breast tissues were applicable in the study, and 2) had a significant correlation 
or concordance of DNA methylation pattern between breast tumor tissue and peripheral blood, 
including leukocytes, plasma and serum. 
 
DNA methylation procedure and assays of the Danish cohort 
DNA methylation array of the blood samples from 10 day-shift workers and 10 night-shift workers were 
generated with Illumina 27k. The details of the method were previously described in a pilot study Zhu11 
(7). In the study, Illumina Infinium Methylation Assay was used for genome-wide methylation array, with 
50 ng of genomic DNA gathered from each subject, and totally 27,578 CpG sites spanning 14,495 genes 
were covered. CpG sites that tested in this study were located with the proximal promoter regions, with 
average distance 389 bp from the transcription start site.  
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Review on cohort studies of association between each overlapped gene and breast cancer 
Cohort studies of each genes overlapping in both gene sets will be searched. Review on the cohort 
studies will be performed to discuss whether that gene might be a precursor of breast cancer. This 




Concordance based on the previous studies 
The concordance or correlation of DNA methylation between breast tumor tissues and blood (including 
white blood cells, leukocytes, plasma and serum) was summarized using the correlation coefficient in 
the original study. Studies using methylation frequency as a measurement or other measurement that 
did not provide parameters on correlation were excluded from further analysis. 
 
DNA methylation levels of the candidate genes from the Danish cohort associated with night 
shift work 
DNA methylation level of the selected samples from the Danish cohort was output through software 
Illumina. The difference of DNA methylation level between day workers and night-shift workers was 
analyzed using student t-test in GenomeStudio of Illumina, Inc. All the genes selected in the systematic 
review were analyzed independently. Each selected gene was searched in the methylation dataset of 
Danish cohort, and its difference of methylation level between day workers and night shift workers was 
checked for significance. Pathway analysis on the interactions of the methylated genes were performed 
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to further study the impact of night shift work on biological pathway using software tool Ingenuity 
Pathway Analysis (IPA). 
 
Overlapping of genes from the two studies 
If the association between breast cancer and DNA methylation of the candidate genes that had 
significant concordance of DNA methylation between breast tumor tissue and blood can be verified by 
our statistical analysis of the DNA methylation pattern in Danish cohort, Venn’s diagram was utilized to 
visualize the overlap between the two groups of genes. The genes that appears in both groups might be 




Systematic review of concordance of DNA methylation patterns between breast tumor tissue 
and blood samples for breast cancer patients 
 
Table 1. Descriptions of the included studies 




Wojdacz et al 
(8) 
2011 Denmark  
Breast tumor tissue 
75 - 
Gene-specific 
methylation Peripheral blood 
Barault et al (9) 2013 America 





Normal breast tissue 
Cho (10) 2010 Turkey 





Normal breast tissue 
Cho (11) 2015 America 
Breast tumor tissue 952 - Gene-specific 
methylation Peripheral blood 1021 1036 
Radpour et al 
(12) 
2011 Switzerland 




Blood (serum) 20 




Breast tumor tissue 262 - Gene-specific 
methylation Peripheral blood 942 500 
2010 India Breast tumor tissue 100 - 
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Sharma et al 
(14) 
Normal breast tissue - Gene-specific 
methylation Blood (serum) 30 
 
Totally 524 articles were found in PubMed with key words “DNA methylation; blood; breast cancer” 
from 1991 to March 11th, 2020. Related articles were also reviewed for eligibility. After reviewing the 
title and abstract of articles, 42 papers were selected. 7 of the 42 studies met our criteria for further 
study after reading the whole paper. In these 7 papers, only four studies indicated significant 
concordance or correlation of methylation level of specific genes between blood and breast tumor 
tissue. In these seven studies, Woj11 and Pra20 used methylation-sensitive high-resolution melting (MS-
HRM) and PCR to measure the DNA methylation status, Bar13 used PCR and highly quantitative bisulfite 
pyrosequencing, Cho10 and Cho15 used MethyLight and PCR, Rad11 used PCR and mass spectrometry 
to measure the methylation proportion, and Sha10 used methylation-sensitive PCR (MS-PCR) to 
measure the methylation status. 
 
In the eligible studies, totally 22 candidate genes and 3 repetitive elements were studied and their 
methylation levels were measured and compared among different tissues. Among the 22 candidate 
genes and differentially methylated regions (including BRCA1, APC, RASSF1A, GRB10, H19, KvDMR, 
SNRPN/SNURF, IGF2, HIN1, CDH1, RARβ, TWIST1, CyclinD2 [CCND2], BIN1, BMP6, CST6, ESR-b, GSTP1, 
P16 [CDKN2A], P21 [CDKN1A], TIMP3, MGMT), 8 genes, IGF2 (including IGF2 DMR0 and IGF2 DMR1), 
BMP6, BRCA1, CST6, GSTP1, P16 (alias: CDKN2A), TIMP3 and MGMT were significantly correlated 
between blood and breast tumor tissue in breast cancer patients. Two of the three repetitive elements 
in the selected studies, LINE1 and Sat2M1, also showed significant concordance between blood and 
breast tumor tissue. Since our array did not measure repetitive elements, these two repetitive elements 
were not eligible for further analysis. 
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DMR2 0.50 0.0261 
BMP6 Rad11 R-square linear 7.5E-4 <0.05 4.929239 
BRCA1 
Rad11 R-square linear 0.307 <0.05 
25.60556 Pra20 - - <0.001 
Sha10 r 0.94 <0.001 
CST6 Rad11 R-square linear 0.078 >0.05 0.964586 
GSTP1 
Rad11 R-square linear 0.365 <0.05 
-33.06441 
Sha10 r 0.90 <0.001 
P16 
(CDKN2A) 
Rad11 R-square linear 0.014 <0.05 23.98066 
TIMP3 Rad11 R-square linear 0.18 <0.05 -5.571209 









0.32 0.046 - 
 
DNA methylation pattern in the peripheral blood of Danish cohort 
Characteristics of the study population selected from Danish cohort was described in the Table 3. Age 
and total folate intake of the day workers and night shift workers were not significantly different.  
 








(mean ± SEM years) 
55.17±0.33 55.26±0.91 0.9168 
Total folate intake 
(mean ± SEM μg/day) 
373.2±14.57 367.4±34.75 0.8720 
 
In the analysis of DNA methylation array, totally 5409 CpG sites spanning over 4750 genes were found to 
have differential methylation level between day workers and long-term night shift workers. Among all 
the significantly differentially methylated CpG sites, 66.4% of them corresponding to 3593 methylated 
loci spanning 3196 genes, were hypermethylated, which means that the methylation level was higher 
than the normal, while the remaining 33.6% (1816 loci spanning 1613 genes) were hypomethylated, 
which means lower level than the normal.  
 
Overlapping genes of the two gene sets  
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The overlapped genes between the DNA methylation array and eligible genes in the systematic review 
were found by manually searching for the genes in our dataset. Totally seven of the eight genes can be 
found in our gene sets without any cut-off. Significant level of the different methylation level was set at 
|DiffScore|> 13. Five genes, BRCA1, IGF2, GSTP1, P16 (CDKN2A) and MGMT, appeared in both gene sets 
and showed significant different methylation level between day workers and night shift workers.  
 
Figure 1. Venn diagram: overlapped genes in the two datasets 
 
The yellow circle represents the genes from our DNA methylation array that had different methylation level between 
day and night shift workers. 4750 genes were significantly differentially methylated between the 10 pairs of  day 
workers and night shift workers. The blue circle represents the genes included in the systematic review. The red circle 
represents the genes of which the methylation level was significantly correlated between peripheral blood and breast 
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tumor tissues in breast cancer patients. The overlapped deep color circle represents the genes that appears in both 
datasets. The areas of the circles did not reflect the proportion of genes in different gene sets. 
 
The pathway analysis in Zhu11 (7) showed that the network of interactions, designated as “DNA 
replication, recombination, and repair, gene expression, behavior” by IPA software, was significantly 
enriched in 35 genes that were differentially methylated in night shift workers compared to day 
workers. Interestingly, two genes appearing in the overlapped sets, P16 (CDKN2A) and MGMT were also 
among the aforementioned 35 genes.  
 
Review on cohort studies that explored the relationship between methylation of specific 
genes and breast cancer 
Keywords were each gene symbol plus “methylation; breast cancer; cohort”. Studies were from 1998 to 
March 11th, 2020. 
 
IGF2. Keywords “IGF2; methylation; breast cancer” was used instead because of the limit amount of 
available papers in PubMed. Ito08 used the blood sample collected 2-5 years prior to breast cancer 
diagnosis from EPIC cohort and screened them to measure the hypomethylation status of IGF2. (15) The 
results found that IGF2 hypomethylation was not constitutively present in the blood before the 
diagnosis of breast cancer. It suggested that hypomethylation of IGF2 might be an acquired epimutation 
rather than precursor for breast cancer. 
 
BRCA1. Totally 58 studies were found using the keywords “BRCA1; methylation; breast cancer; cohort”. 
There were inconsistent results among the few studies that provided information on association 
between BRCA1 promoter methylation and breast cancer development. A study in Vietnamese women 
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with breast cancer (16) gathered 79 pairs of breast tumor samples and matched adjacent normal breast 
tissues from women who underwent mastectomy at the Department of Pathology, National Cancer 
Hospital K, Hanoi, between 2014 and 2015. The investigators tested the significance of differential 
methylation frequency of BRCA1, RASSF1A and GSTP1 between breast tumor tissues and adjacent 
normal tissue, and found significantly higher methylation frequency of GSTP1 in breast tumor tissue 
than that in matched normal tissues, but no significantly differential methylation level of BRCA1. In 
Pra20 (13), which was also included in our systematic review, BRCA1 methylation status was significantly 
associated with breast cancer among triple-negative breast cancer patients as well as in ER-negative 
breast cancer patients, but among the overall patients, there was no significant association between 
BRCA1 methylation and breast cancer risk. It implicated that BRCA1 methylation might be a biomarker 
for clinicopathological characteristic rather than diagnosis or detection for breast cancer. In a meta-
analysis (17) of four prospective cohort studies including MCCS, EPIC-Italy, EPIC-IARC and PLCO, BRCA1 
promoter methylation in blood was not significantly associated with breast cancer risk (p=0.88).  
 
GSTP1. Aside from the VuT18 (16) aforementioned, a case-control study on a cohort of Egyptian females 
(18) showed that GSTP1 methylation status was significantly higher in breast cancer patients than that in 
normal controls. One case-control study (19) nested in prospective New York University Women's 
Health Study cohort found no significantly differential methylation of GSTP1 in serum between cases 
and controls.  
 
P16 and MGMT. No eligible studies were found aside from the studies include in our systematic review. 
 
Summary of the functions of those genes in the carcinogenesis of breast cancer 
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IGF2 gene participates in the expression of a protein called insulin-like growth factor 2 (IGF2) that plays 
important role in growth and development during embryogenesis and promoting the cell growth and 
cell proliferation in different tissues including breast tissues. IGF2 is also an imprinted gene, of which 
only the paternally inherited copy is active in cells. (20) IGF ligands (including IGF1 and IGF2) contributed 
to tumorigenesis of various types of cancer by binding to and activating IGF-1R, then lead to two 
signaling pathways: PI3K/AKT and Ras/MAPK. In estrogen receptor positive (ER+) breast cancer and 
HER2 positive breast cancer, studies showed that IGF signaling might be associated with drug resistance. 
(21)  
 
BRCA1 germline mutation plays critical role in the development of breast cancer and ovarian cancer and 
its function was well-studied in previous studies. Although there are inconsistent results on the 
association between BRCA1 methylation and breast cancer risk, BRCA1 is one of the most studies genes 
in carcinogenesis, especially its role in breast cancer and ovarian cancer. BRCA1 and BRCA2, the breast 
cancer susceptibility genes, are tumor suppressor genes, and their mutation can lead to malignancies 
including various types of cancers. BRCA1 has been proved by the large amount of studies as the genes 
that participated in regulating DNA repair and preventing uncontrolled cell growth that might lead to 
cancer. Studies showed that BRCA1 participated in the tumorigenesis though suppressing IGF-1R 
promoter activity and decreasing endogenous IGF-1R level in breast-cancer cell line. (22) There was 
experimental evidence on the relations between BRCA1 mutations and dysregulation of the 
progesterone/RANK/RANKL/OPG system that might play an important role in carcinogenesis of breast 
cancer. (23) 
 
GSTP1 encoded protein belongs to GSTs, a family of enzymes that participates in detoxification. GSTP1 
proteins are thought to play important role in xenobiotic metabolism and susceptibility to some diseases 
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including cancer. One study showed that GSTP1 was associated with activation of AMPK thereby 
impairing the oncogenic signaling pathway, and it was also involved in the inhibition of mTOR signaling. 
(24) 
 
P16, also called CDKN2A, is a gene that is frequently mutated or deleted in a wide range of tumors, and 
is thought to be a tumor suppressor gene. In a study on ER-positive, HER2-negative breast cancer, 
investigators found that loss of CDKN2A (p16) was correlated with abnormal CDK4/6/RB pathway, which 
could lead to deregulated kinase activity and development of diseases including cancer. (25) 
 
MGMT is known to be a DNA repair gene. The protein encoded by MGMT catalyzes the reaction of 
transferring methyl groups from O(6)-alkylguanine and other methylated moieties of the DNA to its own 
molecule thereby repairs the toxic lesions. Methylation of MGMT promoter is associated with diseases 
such as colorectal cancer, lung cancer and breast cancer. MGMT was involved in DNA damage signaling 




Methylation status of five genes, IGF2, BRCA1, P16 (CDKN2A), GSTP1 and MGMT showed significant 
concordance between peripheral blood and breast tumor tissues in breast cancer patients. This result 
implicated that these genes might be utilized as potential biomarkers for non-invasive detection and 
diagnosis of breast cancer. However, some limitations of this study need to be specified. First, some 
genes displayed inconsistent differential methylation pattern in different studies. For example, BCRA1 
methylation was significantly correlated between blood and breast cancer in Pra20 (13) among triple-
negative breast cancer patients and ER-negative breast cancer patients, but for all the samples in the 
study regardless of their clinicopathologic status the association of BRCA1 methylation in blood sample 
with breast cancer was not significant. In our systematic review, subgroup analysis on clinical stage and 
subtypes of cancer was not conducted because information was limited or sample size was too small. In 
Rad11, another cohort consisting 36 plasma samples from breast cancer patients and 30 plasma samples 
from healthy women showed that methylation proportion of BRCA1, CST6, GSTP1, P16 and TIMP3 were 
significantly higher in breast cancer patients than that in normal controls. However, in Bro10, a nested 
case-control study aforementioned, found no significant differential GSTP1 methylation pattern 
between cases and controls. Second, blood samples and tumor tissues in some the studies, such as 
Pra20 and Cho15, was not collected from the same subject, which might introduce bias due to individual 
difference. But these two studies had sufficient sample size to detect population level association. 
Besides, the different types of blood sample might also affect the results. Rad11 used plasma and 
serum, Sha10 used serum, while Bar13 measured leukocyte DNA in peripheral blood. Different methods 
used to measure the methylation pattern were also possible to introduce bias because technologies had 
different coverage of CpG sites and sensitivity as well as parameter. However, due to the limited 
number of studies, subgroup analysis on different types of blood samples and methods was not feasible. 
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Based on our dataset, whether there is causal relationship between night shift work and DNA 
methylation was not clear and no temporality of the two events was established, thereby further studies 
using prospective cohort study design might be able to answer this question. According to the pilot 
study (7) using the same dataset with this study did show significant association between night shift 
work and DNA methylation of some genes.  
 
In this study, review on prospective studies that study DNA methylation and breast cancer was also 
included. For each gene, there is limited amount of studies available in the PubMed. From the eligible 
studies, either there was no information on temporality of methylation status and breast cancer onset, 
or the evidence showed no significant association between methylation and breast cancer risk. 
Therefore, we cannot make any conclusion on the potential precursor of the genes discussed 
abovementioned. To answer the unsolved questions in this study, prospective cohort study with large 
sample size needs to be carried on. 
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